Wockhardt is running out of options
Faced with a cash crunch, the Mumbai-based drug maker has only its research to fall back on. Will it yield a blockbuster?
Subscribe to read this story
We publish over 500 original, detailed stories every year on startups, corporates, stock markets and economic current affairs.
$99 for one year
Not ready to subscribe? Sign up for a free account
We value our free readers. Read 100+ stories every year.
More in Business
You may also like
Why quick delivery of medicines will be difficult to scale
Quick-commerce apps are likely to run into regulations and poor order volumes as they try to grow this business.
Why is Swiggy catching flak for its latest quick-delivery promise?
The food and grocery delivery company’s idea of providing prescription drugs in 10 minutes is facing resistance from traditional pharma players.
For Sun Pharma’s Dilip Shanghvi, specialty drugs remain the magic bullet
Specialty drugs are fast becoming a lucrative market globally. And India’s largest drugmaker has done well to make the most of this opportunity so far. But it’s too soon to rest easy.
